Hepatobiliary Surgery and Nutrition

Papers
(The H4-Index of Hepatobiliary Surgery and Nutrition is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights245
Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma88
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)53
Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease52
Clinical practice of transarterial chemoembolization for hepatocellular carcinoma: consensus statement from an international expert panel of International Society of Multidisciplinary Interventional O44
Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma41
International expert consensus on laparoscopic pancreaticoduodenectomy*40
Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel?39
Liver venous deprivation versus portal vein embolization before major hepatectomy: future liver remnant volumetric and functional changes37
Neuroendocrine liver metastases: a contemporary review of treatment strategies33
Hepatocellular carcinoma in non-alcoholic fatty liver disease—a review of an emerging challenge facing clinicians29
A review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis24
Optimization of the future remnant liver: review of the current strategies in Europe24
Biliary complications after liver transplantation: current perspectives and future strategies24
Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy23
Probiotics VSL#3 are effective in reversing non-alcoholic steatohepatitis in a mouse model23
Diagnosis-related Groups (DRG) pricing and payment policy in China: where are we?20
Development of a machine learning model to predict early recurrence for hepatocellular carcinoma after curative resection20
Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients19
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease19
When a new definition overhauls perceptions of MAFLD related cirrhosis care19
Gd-EOB-DTPA-enhanced MRI radiomic features for predicting histological grade of hepatocellular carcinoma19
0.026663064956665